Biotech entity
Every one of those 1 sits in a single category, clinical-trial. GBM-LODER is most often covered alongside FiscalAI, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention GBM-LODER, all published on August 16, 2026.
Last mentioned: Aug 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. GBM-LODER is most often covered alongside FiscalAI, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention GBM-LODER, all published on August 16, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GBM-LODER. Shared-story counts are live from our verified record — not editorial picks.
Silexion reports quarterly results
Silexion reported a $5.17 loss per share, beating consensus estimates by $16.03; shares fell to $0.42.
Maxim Group downgrades to Hold
Maxim Group lowered Silexion Therapeutics from a Strong-Buy rating to a Hold rating.
Weiss Ratings reiterates Sell (E+)
Weiss Ratings reiterated a Sell (E+) rating on Silexion Therapeutics shares.
Silexion reported a narrower-than-expected loss of $5.17 per share, but analysts downgraded the stock to Hold. Its RNAi LODER candidates remain preclinical or Phase I, and a $0.42 share price may constrain funding for further oncology development.
Source: tickerreport.com · dailypolitical.com
GBM-LODER is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
